The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.
The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
Through the deal, Helomics aims to build a predictive model of prostate cancer drug response based on a combination of genomic and spectroscopy data.
The companies will use their respective technologies in a study investigating the associations between ovarian cancer and the gut microbiome.
Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.
Helomics' managing executives will remain to manage TumorGenesis, Precision's newly formed subsidiary for cancer diagnostics and therapy.
The assay is based on Ariel's Smart-MD bioinformatics platform, which combines patient symptoms and history with next-generation sequencing data.
The companies partnered last month to develop new personalized cancer diagnostics using the Helomics D-Chip bioinformatics platform.
At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.
The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.
Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.
In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.